The NIAID said the total funding for the leadership group cooperative agreement could be worth as much as $62 million through 2019. Infections with resistant bacteria are becoming more common in healthcare and community settings, with many bacteria resistant to more than one class of antibiotics.
“Antibacterial resistance is a serious and growing public health threat that is endangering the global medical community’s ability to effectively treat conditions ranging from simple skin infections to tuberculosis,” Anthony Fauci, the director of the NIAID, said. “Through this new clinical research network, we will strengthen our existing research capacity and address the most pressing scientific priorities related to antibacterial resistance.”
Vance Fowler of Duke University and Henry Chambers of the University of California, San Francisco, will co-lead the leadership group. The group is expected to test diagnostics, examine best practices in infection control programs to prevent the spread and development of resistant infections, perform clinical trials to optimize currently licensed antibacterial drugs to reduce resistance risk and conduct early-stage clinical evaluation of new antibacterial drugs.
A Duke University operations center will anchor the network and provide necessary technical support.
The leadership group cooperative award will complement NIAID’s extensive antimicrobial resistance portfolio, which includes clinical trials, clinical research and product development related to antibacterial drugs.